Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar

Antimicrob Agents Chemother. 2018 Feb 23;62(3):e01984-17. doi: 10.1128/AAC.01984-17. Print 2018 Mar.

Authors

Affiliations

¹ Advanced Molecular Research Centre, Department of Medical Research, Yangon, Myanmar.
² National Tuberculosis Program, Department of Public Health, Naypyitaw, Myanmar.
³ Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
⁴ International Tuberculosis Research Center, Changwon, Republic of Korea cosmosljs@gmail.com.

No abstract available

Keywords: MDR-TB; Myanmar; XDR-TB; pyrazinamide.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Amidohydrolases / genetics*
Amidohydrolases / metabolism
Antitubercular Agents / pharmacology*
Drug Resistance, Multiple, Bacterial / genetics*
Fluoroquinolones / pharmacology
Gene Expression
Humans
Microbial Sensitivity Tests
Mutation
Myanmar / epidemiology
Mycobacterium tuberculosis / drug effects*
Mycobacterium tuberculosis / genetics
Mycobacterium tuberculosis / growth & development
Mycobacterium tuberculosis / metabolism
Pyrazinamide / pharmacology*
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / epidemiology
Tuberculosis, Multidrug-Resistant / microbiology

Substances

Antitubercular Agents
Fluoroquinolones
Pyrazinamide
Amidohydrolases
PncA protein, Mycobacterium tuberculosis